Navigation Links
BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board
Date:3/25/2011

NEWARK, N.J., March 25, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTC Bulletin Board: BONU), a specialty life science technology-based company, today announced the appointment of Dr. Stephen Holt, M.D., Ph.D, a Distinguished Professor of Medicine (Emeritus) and a medical practitioner in New York State, as the Company's Vice Chairman of the Board and Independent Director. Dr. Holt is an independent consultant to the pharmaceutical and dietary supplement industry, and a Board-certified Internist and Sub-Specialist in the United States, Canada, United Kingdom and European Union.

"We are extremely pleased to welcome Dr. Holt to our Board. He is an esteemed member of the medical community and has established relationships with healthcare facilities worldwide. As an added benefit, his experience in the medical community can help us accelerate the commercialization of our recent EPA-approved Hospital-Grade Ygiene® ," said Stephen J. Browand, Chairman and CEO of BioNeutral Group, Inc. "The addition of Dr. Holt also increases the number of independent directors to our Board, which is in line with our commitment to increase transparency and adhere to the highest levels of corporate governance."

Dr. Holt is currently a Consultant Physician in Gastroenterology, Medicine and Nutrition, New York; and a Board member of Integrative Medicine Asia; Global Foundation of Integrative Medicine; and the European Society of Anti-Aging Medicine. Dr. Holt has published many peer-review papers in medicine and is a best-selling author with twenty books in national and international distribution. Dr. Holt is a frequent lecturer at scientific meetings and healthcare facilities throughout the world.  He is the founder of the Holt Institute of Medicine and Lieutenant Grand Hospitaller of the Holy Order of the Sovereign Knights of St. John of Jerusalem. Dr. Holt is an Honors Graduate of Liverpool University Medical School, England.

About BioNeutral Group, Inc.Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene® and Ogiene®, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace.  BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene® brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also  permitted to be sold in the UK, France and Sweden. AutoNeutral is a Registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com.

Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393

Follow us on Twitter: http://twitter.com/bioneutralgroup

Forward-Looking Statements

This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene®-206 BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and will soon be available for sale in the United States.Media Contact:Matt RizzettaNorth 6th Agencymrizzetta@north6thagency.com718-744-7138Investor Relations Contact:Jeff RamsonProActive Capital Resources Group, LLCjramson@proactivecrg.com212-792-4294  FOR THE COMPANY:Stephen J. BrowandBioNeutral Group, Inc.steve@bioneutralgroup.com973-286-2899
'/>"/>

SOURCE BioNeutral Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioNeutral Enters into Global Sales and Distribution Agreement with Raymond Associates to Expand Market for Military-Grade Ygiene(TM)
2. BioNeutral Group Secures Three Initial Trial Orders for its Ogiene™ Odor Neutralizer & Multi-Purpose Cleaner Product Line
3. BioNeutral Group to Receive Economic Development Incentives
4. Kentucky Hospital Association Solutions Group Outlines Next Steps for BioNeutral Partnership
5. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing
6. BioNeutral Groups CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM In Focus Radio Show Hosted by Dr. Dan Miller
7. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
8. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
9. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
10. BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana
11. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... MedDay, a biotechnology company focused on the treatment of ... as Chairman of its Board of Directors. Catherine ... who contributed to the rapid development of the Company since ... her career in strategy consulting and investment banking in ...  She held C-Suite level roles in some of ...
(Date:4/26/2016)... ... April 26, 2016 , ... BaseHealth ... has joined the company as Chief Business Officer. Arianpour, a genomics pioneer and ... to market, was most recently Chief Commercial Officer of Pathway Genomics. He has ...
(Date:4/26/2016)... ... April 26, 2016 , ... Mr. Palmer created the RPO business for ... multi-million dollar, multi-year managed services contract in the U.S. intelligence community with The SI ... team,” said John Younger, founder of Accolo. “We are growing and his experience ...
(Date:4/26/2016)... (PRWEB) , ... April 26, 2016 , ... ... announced receipt of a significant operating grant from 1Plus12 Corporation. The grant will ... commence pre-proposal activities as outlined on the organization's website http://www.ivsci.org , ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):